Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
Interventions: DRUG: ganetespib|DRUG: paclitaxel|BIOLOGICAL: trastuzumab|BIOLOGICAL: pertuzumab
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: National Cancer Institute (NCI)|Synta Pharmaceuticals Corp.|New York University Cancer Institute